Nefrologia最新文献

{"title":"Niveles de creatinina elevados y cistatina normales en un paciente que recibe ribociclib","authors":"","doi":"10.1016/j.nefro.2024.02.001","DOIUrl":"10.1016/j.nefro.2024.02.001","url":null,"abstract":"","PeriodicalId":18997,"journal":{"name":"Nefrologia","volume":"44 5","pages":"Pages 762-764"},"PeriodicalIF":2.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0211699524000079/pdfft?md5=51cb0d6e5e0a65114a717376eb818cf8&pid=1-s2.0-S0211699524000079-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139878831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Coste-efectividad del ciclosilicato de sodio y zirconio para el tratamiento de la hiperpotasemia en pacientes con enfermedad renal crónica o insuficiencia cardiaca en España","authors":"","doi":"10.1016/j.nefro.2024.02.006","DOIUrl":"10.1016/j.nefro.2024.02.006","url":null,"abstract":"<div><h3>Background and objective</h3><p>Hyperkalemia (HK) is an electrolyte disturbance in the concentration of potassium ions (K⁺), whose risk increases in patients with chronic kidney disease (CKD) or heart failure (HF) and/or in patients being treated with renin-angiotensin-aldosterone system inhibitors (RAASi). The new oral K⁺ chelators offer a safe and effective treatment to maintain normokalemia in these patients. The objective of the analysis is to estimate the cost-effectiveness of sodium zirconium cyclosilicate (SZC) for the treatment of chronic HK in patients with CKD or HF versus standard treatment (calcium polystyrene sulfonate and lifestyle modifications) from the perspective of the Spanish National Health System.</p></div><div><h3>Materials and methods</h3><p>Two microsimulation models reflecting the natural history of CKD and HF were used. In both models, K⁺ levels were simulated individually. Based on efficacy (reduction of K⁺ levels), quality of life of patients (utilities according to health states, and disutilities of events derived from each pathology and adverse events [AEs] of treatment) and costs considered (cost of treatment for HK, of RAASi treatment and its modification, health states, management of events derived from each pathology, HK episodes, and AEs treatment) (€, 2022), clinical benefit (quality-adjusted life years [QALYs]) and cost results were obtained. A time horizon of the patient's lifetime was used and a discount rate of 3% was applied for costs and outcomes.</p></div><div><h3>Results</h3><p>SZC is a more effective option in both pathologies, with a difference in QALYs of 0.476 in CKD and 0.978 in HF compared to standard treatment, and it represents an incremental cost of € 3,616 and € 14,749, respectively, obtaining an incremental cost-utility ratio of € 7,605 /QALY in CKD and € 15,078 /QALY in HF.</p></div><div><h3>Conclusions</h3><p>SZC is a cost-effective alternative for the treatment of HK in patients with CKD or HF, taking into account the reference efficiency values commonly used in Spain.</p></div>","PeriodicalId":18997,"journal":{"name":"Nefrologia","volume":"44 5","pages":"Pages 709-720"},"PeriodicalIF":2.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0211699524000171/pdfft?md5=313960772570e6858aa49f0328ecbc74&pid=1-s2.0-S0211699524000171-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140092850","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"La implantación de la cardionefrología en España es una urgencia sanitaria","authors":"","doi":"10.1016/j.nefro.2024.05.007","DOIUrl":"10.1016/j.nefro.2024.05.007","url":null,"abstract":"","PeriodicalId":18997,"journal":{"name":"Nefrologia","volume":"44 5","pages":"Pages 619-622"},"PeriodicalIF":2.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0211699524000420/pdfft?md5=9650813087a2833b2f01d6a147f82ece&pid=1-s2.0-S0211699524000420-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141142376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nefritis intersticial cariomegálica","authors":"","doi":"10.1016/j.nefro.2024.03.003","DOIUrl":"10.1016/j.nefro.2024.03.003","url":null,"abstract":"","PeriodicalId":18997,"journal":{"name":"Nefrologia","volume":"44 5","pages":"Pages 743-744"},"PeriodicalIF":2.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0211699524000249/pdfft?md5=99367f51119dd7c12efd7a292f55d78d&pid=1-s2.0-S0211699524000249-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140272218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mind the gap in kidney care: Translating what we know into what we do","authors":"Valerie A. Luyckx ,&nbsp;Katherine R. Tuttle ,&nbsp;Dina Abdellatif ,&nbsp;Ricardo Correa-Rotter ,&nbsp;Winston W.S. Fung ,&nbsp;Agnès Haris ,&nbsp;Li-Li Hsiao ,&nbsp;Makram Khalife ,&nbsp;Latha A. Kumaraswami ,&nbsp;Fiona Loud ,&nbsp;Vasundhara Raghavan ,&nbsp;Stefanos Roumeliotis ,&nbsp;Marianella Sierra ,&nbsp;Ifeoma Ulasi ,&nbsp;Bill Wang ,&nbsp;Siu-Fai Lui ,&nbsp;Vassilios Liakopoulos ,&nbsp;Alessandro Balducci ,&nbsp;for the World Kidney Day Joint Steering Committee","doi":"10.1016/j.nefro.2024.05.002","DOIUrl":"10.1016/j.nefro.2024.05.002","url":null,"abstract":"<div><p>Historically, it takes an average of 17 years to move new treatments from clinical evidence to daily practice. Given the highly effective treatments now available to prevent or delay kidney disease onset and progression, this is far too long. The time is now to narrow the gap between what we know and what we do. Clear guidelines exist for the prevention and management of common risk factors for kidney disease, such as hypertension and diabetes, but only a fraction of people with these conditions worldwide are diagnosed, and even fewer are treated to target. Similarly, the vast majority of people living with kidney disease are unaware of their condition, because in the early stages it is often silent. Even among patients who have been diagnosed, many do not receive appropriate treatment for kidney disease. Considering the serious consequences of kidney disease progression, kidney failure, or death, it is imperative that treatments are initiated early and appropriately. Opportunities to diagnose and treat kidney disease early must be maximized beginning at the primary care level. Many systematic barriers exist, ranging from patient to clinician to health systems to societal factors. To preserve and improve kidney health for everyone everywhere, each of these barriers must be acknowledged so that sustainable solutions are developed and implemented without further delay.</p></div>","PeriodicalId":18997,"journal":{"name":"Nefrologia","volume":"44 5","pages":"Pages 731-742"},"PeriodicalIF":2.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0211699524000377/pdfft?md5=694bbd257e5ed54a9b863696d5a43532&pid=1-s2.0-S0211699524000377-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142163955","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pielonefritis aguda en paciente trasplantado renal secundaria a infección por Delftia acidovorans: a propósito de un caso","authors":"","doi":"10.1016/j.nefro.2022.12.010","DOIUrl":"10.1016/j.nefro.2022.12.010","url":null,"abstract":"","PeriodicalId":18997,"journal":{"name":"Nefrologia","volume":"44 4","pages":"Pages 593-594"},"PeriodicalIF":2.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0211699522002053/pdfft?md5=73ad6f2fcbe66aa365b982ee7c24d505&pid=1-s2.0-S0211699522002053-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46964280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeting colonic BK channels: A novel therapeutic strategy against hyperkalemia in chronic kidney disease","authors":"","doi":"10.1016/j.nefro.2023.01.001","DOIUrl":"10.1016/j.nefro.2023.01.001","url":null,"abstract":"","PeriodicalId":18997,"journal":{"name":"Nefrologia","volume":"44 4","pages":"Pages 594-596"},"PeriodicalIF":2.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0211699523000012/pdfft?md5=26c511d85510be6f636f623de20bb35e&pid=1-s2.0-S0211699523000012-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"55187953","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Karyomegalic nephropathy – Letter to the Editor","authors":"","doi":"10.1016/j.nefro.2023.04.002","DOIUrl":"10.1016/j.nefro.2023.04.002","url":null,"abstract":"","PeriodicalId":18997,"journal":{"name":"Nefrologia","volume":"44 4","pages":"Pages 604-605"},"PeriodicalIF":2.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0211699523000632/pdfft?md5=3b167a809edef0839bbc18df4149678a&pid=1-s2.0-S0211699523000632-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"55187982","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Individualización y desafíos para la hemodiálisis de la próxima década","authors":"","doi":"10.1016/j.nefro.2023.09.003","DOIUrl":"10.1016/j.nefro.2023.09.003","url":null,"abstract":"","PeriodicalId":18997,"journal":{"name":"Nefrologia","volume":"44 4","pages":"Pages 459-464"},"PeriodicalIF":2.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0211699523001443/pdfft?md5=dd7a60329517676941acadf6ca6099f0&pid=1-s2.0-S0211699523001443-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135298865","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Irbesartan restored aquaporin-1 levels via inhibition of NF-kB expression in acute kidney injury model","authors":"Busra Candan ,&nbsp;Ilter Ilhan ,&nbsp;Emine Sarman ,&nbsp;Murat Sevimli","doi":"10.1016/j.nefro.2023.11.005","DOIUrl":"10.1016/j.nefro.2023.11.005","url":null,"abstract":"<div><h3>Introduction</h3><p>Acute kidney injury (AKI) is a serious pathology that progress with dysfunction of regulating blood pressure and fluid balance, concentrating urine due to decrement of aquaporin-1 (AQP) levels during the inflammation process. Irbesartan (IRN), angiotensin receptor blocker, is widely used in the treatment of hypertension, which also has anti-inflammatory, antioxidant and anti-apoptotic properties. The aim of this study is to investigate the protective effects of IRN in lipopolysaccharide (LPS)-induced kidney injury.</p></div><div><h3>Material and methods</h3><p>Twenty-four rats divided into three groups as control, LPS and LPS<!--> <!-->+<!--> <!-->IRN group. After 6<!--> <!-->h of LPS administration, rats were sacrificed. Blood samples and half of the kidney tissues were collected for biochemical analysis and remaining tissues were taken for histopathological and immunohistochemical analysis.</p></div><div><h3>Results</h3><p>In the LPS group, glomerular congestion and shrinkage, degeneration of distal tubules, mononuclear cell infiltration, cellular debris and intense proteinous accumulation in the tubules, increased expressions of Cas-3, nuclear factor kappa beta-p65 (NF-kB p65), levels of creatinin, TOS, OSI and decreased levels of TAS, AQP-1 were found significantly. IRN treatment reversed all these parameters. IRN's restorated AQP-1 levels by its anti-inflammatory, antioxidant and anti-apoptotic effects due to inhibiting NF-kB expression.</p></div><div><h3>Conclusion</h3><p>This study suggests that IRN can be used in conditions affecting the kidneys such as AKI. Further studies needed for detailed molecular investigation of IRN at different doses and durations.</p></div>","PeriodicalId":18997,"journal":{"name":"Nefrologia","volume":"44 4","pages":"Pages 540-548"},"PeriodicalIF":2.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0211699523001765/pdfft?md5=1a73f917f523cbbdc48971de3c1b4b06&pid=1-s2.0-S0211699523001765-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141622893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}